Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study
Schöffski, Patrick × Besse, B Gauler, T de Jonge, M J A Scambia, G Santoro, A Davite, C Jannuzzo, M G Petroccione, A Delord, J-P #
Kluwer Academic Publishers
Annals of Oncology vol:26 issue:3 pages:598-607
This multi-centre phase II trial assessed the activity, safety (CTCAE 3.0) and pharmacokinetics (PK) of the pan-Aurora kinase inhibitor danusertib hydrochloride (PHA-739358) in breast (BC), ovarian (OC), pancreatic (PC), colorectal (CRC), small-cell (SCLC) and non-small-cell lung (NSCLC) cancers.